Transmembrane G protein-coupled receptor 30 (GPR30) gene polymorphisms in Korean Women with Ovarian Cancer: An experimental study

Purpose: To compare genetic distribution of fourteen (14) G protein-coupled receptor 30 (GPR30) single-nucleotide polymorphisms (SNPs) in patients with ovarian cancer or benign gynecological disease. Materials and Methods: We examined 117 Korean females with postoperative specimens available for DNA extraction. We used predesigned PCR/Sanger or Sequencing Primer and TaqMan SNP Genotyping Assays for SNP genotyping of the GPR30 gene and performed immunohistochemical staining for assessing GPR30 protein expression. We analyzed linkage disequilibrium (LD) and evaluated differences in genotype and allele frequency between the two groups. Results: We observed no differences in genotype distribution and allele frequency between the two groups. Two LD blocks were determined in both groups. All specimens of both groups revealed intensive staining with a high percentage of positive cells exhibiting GPR30 expression. Conclusions: This study could not demonstrate differences in the genetic distribution of fourteen GPR30 gene polymorphisms in Korean women with ovarian cancer and disease-free controls.

Ovarian cancer; G protein–coupled receptor 30; Single-nucleotide polymorphism; Korean

[1] Brewer M.A., Johnson K., Follen M., Gersenson D., Bast R. Jr.: “Prevention of ovarian cancer: intraepithelial neoplasia”. Clin. Cancer Res., 2003, 9, 20.

[2] Vo C., Carney M.E.: “Ovarian cancer hormonal and environmental risk effect”. Obstet. Gynecol. Clin. North. Am., 2007, 34, 687.

[3] Modugno F., Laskey R., Smith A.L., Anderson C.L., Haluska P., Oesterreich S. : “Hormone response in ovarian cancer: time to reconsider as a clinical target?” Endocr. Relat. Cancer., 2012, 19, R255.

[4] Grandien K., Berkenstam A., Gustafsson J.A.: “The estrogen receptor gene: promoter organization and expression”. Int. J. Biochem. Cell Biol., 1997, 29, 1343.

[5] Pedram A., Razandi M., Levin E.R.: “Nature of functional estrogen receptors at the plasma membrane”. Mol. Endocrinol., 2006, 20, 1996.

[6] Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., Prossnitz E.R. “A transmembrane intracellular estrogen receptor mediates rapid cell signaling”. Science, 2005, 307, 1625.

[7] Thomas P., Pang Y., Filardo E.J., Dong J.: “Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells”. Endocrinology, 2005,146,624.

[8] Sandén C., Broselid S., Cornmark L., Andersson K., Daszkiewicz-Nilsson J., Mårtensson UE., et al. : “G protein-coupled estrogen receptor 1/G protein-coupled receptor 30 localizes in the plasma membrane and traffics intracellularly on cytokeratin intermediate filaments”. Mol. Pharmacol., 2011, 79,400.

[9] Long L., Cao Y., Tang L.D.: “Transmembrane estrogen receptor GPR30 is more frequently expressed in malignant than benign ovarian endometriotic cysts and correlates with MMP-9 expression”. Int. J. Gynecol. Cancer, 2012, 22,539.

[10] Smith H.O., Arias-Pulido H., Kuo D.Y., Howard T., Qualls C.R., Lee S.J., et al. : “GPR30 predicts poor survival for ovarian cancer”. Gynecol. Oncol., 2009, 114,465.

[11] Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blu- menstiel B., et al.: “The structure of haplotype blocks in the human genome”. Science, 2002, 296, 2225.

[12] Olde B., Leeb-Lundberg L.M.: “GPR30/GPER1: searching for a role in estrogen physiology”.Trends Endocrinol. Metab., 2009, 20,409.

[13] Giess M., Lattrich C., Springwald A., Goerse R., Ortmann O., Treeck O. : “GPR30 gene polymorphisms are associated with progesterone receptor status and histopathological characteristics of breast cancer patients”. J. Steroid. Biochem. Mol. Biol., 2010, 118, 7.

[14] Korkmaz H.A., Edgünlü T., Eren E., Demir K., Çakir E.D., Çelik S.K., et al. : “GPR30 Gene Polymorphisms Are Associated with Gynecomastia Risk in Adolescents”. Horm. Res. Paediatr., 2015, 83,177.

[15] Kasap B., Öztürk Turhan N., Edgünlü T., Duran M., Akbaba E., Öner G. : “G-protein-coupled estrogen receptor-30 gene polymorphisms are associated with uterine leiomyoma risk”. Bosn. J. Basic. Med. Sci., 2016, 16, 39.

[16] Marjon N.A., Hu C., Hathaway H.J., Prossnitz E.R.: “G protein-coupled estrogen receptor regulates mammary tumorigenesis and metastasis”. Mol. Cancer Res., 2014,12,1644.

[17] Smith H.O., Leslie K.K., Singh M., Qualls C.R., Revankar C.M., Joste N.E., et al. : “GPR30: a novel indicator of poor survival for endometrial carcinoma”. Am. J. Obstet. Gynecol., 2007,196,386.

[18] Kolkova Z., Casslén V., Henic E., Ahmadi S., Ehinger A., Jirström K., et al. : “The G protein-coupled estrogen receptor 1 (GPER/GPR30) does not predict survival in patients with ovarian cancer”. J. Ovarian Res., 2012,18,5.

[19] Albanito L., Madeo A., Lappano R., Vivacqua A., Rago V., Carpino A., et al. : “G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells”. Cancer Res., 2007, 67, 1859.

[20] Hunn J., Rodriguez G.C.: “Ovarian cancer: etiology, risk factors, and epidemiology”. Clin. Obstet. Gynecol., 2012, 55, 3.